U.S.–UK pharma pricing deal guarantees no new Section 232/301 tariffs on UK drugs/medtech into the U.S. through Jan. 19, 2029, subject to conditions.

REGULATORY BRIEFING – U.S.–UK ARRANGEMENT ON PHARMACEUTICAL PRICING

1. What changed

The United States and the United Kingdom concluded an Arrangement on Pharmaceutical Pricing that, among other policy and pricing commitments, includes specific U.S. trade policy commitments affecting tariffs on U.S. imports of UK-origin pharmaceuticals and medical technologies.

Key U.S. trade commitments (Section IV.1 of the Arrangement):

• Section 232 (national security) – Pharmaceuticals and ingredients:
• The ongoing or future Section 232 investigation on imports of pharmaceuticals and pharmaceutical ingredients will result in no tariffs applied to pharmaceutical products (patented and non‑patented) of the United Kingdom during the period January 1, 2026 through January 19, 2029, provided that all major UK pharmaceutical companies enter into and comply with MFN and Tariff Agreements with HHS and Commerce.
• Section 301 (Trade Act of 1974) – Pharmaceuticals:
• The United States will not subject pharmaceutical products (patented and non‑patented) of the United Kingdom to any additional tariffs under Section 301 during the period December 1, 2025 through January 19, 2029.
• Section 232/301 – Medical technologies:
• The United States will not subject medical technologies of the United Kingdom to any additional tariffs under Section 232 or Section 301 during the period December 1, 2025 through January 19, 2029.
• All of the above periods may be extended by mutual written decision of the Parties.

These are binding policy commitments that directly affect potential additional duties (e.g., trade‑remedy‑type surcharges) on U.S. imports of UK-origin pharmaceuticals and medical technologies. They do not change base MFN duty rates in the HTSUS but limit the application of additional Section 232/301 duties and related Chapter 99 provisions for covered UK-origin products during the specified periods.

2. Affected products

The Arrangement does not list specific HTS codes but defines affected products by category and origin:

A. Pharmaceuticals and pharmaceutical ingredients (UK origin)

• Scope: “Pharmaceutical products (both patented and non‑patented) of the United Kingdom” and “pharmaceuticals and pharmaceutical ingredients” in the context of the Section 232 investigation.
• Likely HTSUS chapters:
• Chapter 29 – Organic chemicals (including active pharmaceutical ingredients (APIs) and key starting materials used as drug substances or intermediates).
• Chapter 30 – Pharmaceutical products (e.g., medicaments, vaccines, immunological products, etc.).
• Examples (illustrative only; not in the Arrangement):
• 3004.90.xx – Medicaments consisting of mixed or unmixed products, for therapeutic or prophylactic uses, put up in measured doses.
• 3002.20.xx – Vaccines for human medicine.
• 2933.xx, 2934.xx – Heterocyclic compounds used as APIs.

B. Medical technologies (UK origin)

• Scope: “Medical technologies of the United Kingdom” (not further defined in the text, but in trade practice typically includes medical devices and related equipment).
• Likely HTSUS chapters:
• Chapter 90 – Optical, photographic, measuring, medical or surgical instruments and apparatus (e.g., 9018, 9019, 9021, 9022).
• Potentially related items in Chapters 84, 85 (e.g., certain diagnostic or therapeutic equipment) depending on classification.

C. Origin requirement

• The commitments apply to products “of the United Kingdom,” i.e., UK-origin goods under U.S. rules of origin.
• Non‑UK origin pharmaceuticals or medical technologies transshipped via the UK are not covered.

3. Rate changes and tariff impacts

A. Base MFN duty rates

• The Arrangement does not modify the MFN base duty rates in the HTSUS for pharmaceuticals or medical technologies.
• Many finished pharmaceutical products under Chapter 30 already enter the U.S. duty‑free under MFN; some APIs and medical devices/equipment may carry positive MFN rates.

B. Additional duties under Section 232 (pharmaceuticals and ingredients)

• Before this Arrangement, a Section 232 investigation on pharmaceuticals and pharmaceutical ingredients could have resulted in additional tariffs (e.g., similar to steel/aluminum surcharges) applied via Chapter 99 HTSUS provisions.
• New commitment:
• Additional Section 232 tariffs on UK-origin pharmaceutical products (patented and non‑patented) will be 0% (i.e., no additional Section 232 duty) from January 1, 2026 through January 19, 2029, provided all major UK pharmaceutical companies enter into and adhere to MFN and Tariff Agreements with HHS and Commerce.
• If the condition is met, importers of UK-origin pharmaceuticals and ingredients will not face incremental Section 232 duty lines during this period.

C. Additional duties under Section 301 (pharmaceuticals and medical technologies)

• New commitments:
• Section 301 – Pharmaceuticals: No additional Section 301 tariffs on UK-origin pharmaceutical products (patented and non‑patented) from December 1, 2025 through January 19, 2029.
• Section 232/301 – Medical technologies: No additional Section 232 or Section 301 tariffs on UK-origin medical technologies from December 1, 2025 through January 19, 2029.
• Practical effect:
• Any new or existing Section 301 actions during this period must exclude UK-origin pharmaceuticals and medical technologies from additional duty lines.
• Importers should not see UK-origin pharmaceuticals or medical technologies assigned to new punitive Chapter 99 tariff lines under Section 301/232 during the covered periods.

D. Possibility of extension or termination

• The Arrangement states that the Parties may decide in writing to extend the no‑tariff periods beyond January 19, 2029.
• The Arrangement may be terminated by either government with six months’ written notice.
• If not extended or if terminated, UK-origin pharmaceuticals and medical technologies could become subject to future Section 232/301 actions, including additional duties via Chapter 99.

4. Key dates

• December 1, 2025:
• Start date for U.S. commitment not to impose additional Section 301 tariffs on UK-origin pharmaceutical products.
• Start date for U.S. commitment not to impose additional Section 232/301 tariffs on UK-origin medical technologies.

• January 1, 2026:
• Start date for U.S. commitment that the Section 232 investigation on pharmaceuticals and pharmaceutical ingredients will result in no tariffs on UK-origin pharmaceutical products through January 19, 2029 (subject to UK company MFN/Tariff Agreements).

• January 19, 2029:
• End date for all three no‑tariff commitments (Section 232 on pharmaceuticals; Section 301 on pharmaceuticals; Section 232/301 on medical technologies), unless extended in writing.

• Ongoing/contingent dates:
• The Arrangement takes immediate effect upon publication.
• Either Party may terminate the Arrangement with six months’ written notice; importers must monitor for any such notice, as it could affect the tariff protections.

5. Required actions for importers, brokers, and compliance teams

A. Confirm and document UK origin

• Ensure robust origin determination for pharmaceuticals, APIs, key starting materials, and medical technologies imported from the UK:
• Maintain supplier origin declarations and long‑term supplier statements.
• Review manufacturing and substantial transformation steps to confirm UK origin under U.S. rules.
• Distinguish UK-origin goods from EU or third‑country goods shipped via the UK.

B. Monitor Section 232/301 measures and Chapter 99 usage

• For the covered period, verify that UK-origin pharmaceuticals and medical technologies are not being:
• Assigned to new or existing Section 232/301 Chapter 99 HTSUS subheadings.
• Assessed additional duties beyond the MFN base rate.
• Broker instructions:
• Explicitly instruct customs brokers that, for qualifying UK-origin pharmaceuticals and medical technologies, no Section 232/301 Chapter 99 codes should be declared unless CBP issues contrary, arrangement‑consistent guidance.
• Require brokers to flag any CBP system prompts or automated assignment of Section 232/301 Chapter 99 codes to UK-origin pharma/medtech lines.

C. Update internal tariff and risk matrices

• Update internal trade‑remedy risk assessments to reflect:
• Zero additional Section 232 duty risk on UK-origin pharmaceuticals from Jan. 1, 2026–Jan. 19, 2029 (subject to conditions).
• Zero additional Section 301 duty risk on UK-origin pharmaceuticals from Dec. 1, 2025–Jan. 19, 2029.
• Zero additional Section 232/301 duty risk on UK-origin medical technologies from Dec. 1, 2025–Jan. 19, 2029.
• Maintain a watchpoint for:
• Any USTR, Commerce, or CBP notices indicating that the conditions (e.g., UK company MFN/Tariff Agreements) have not been met or have been breached.
• Any formal extension of the no‑tariff periods beyond Jan. 19, 2029.
• Any six‑month termination notice issued by either government.

D. Contracting and pricing considerations

• For long‑term supply contracts involving UK-origin pharmaceuticals and medical technologies imported into the U.S.:
• Reflect the reduced risk of additional Section 232/301 duties during the covered periods in pricing and duty‑allocation clauses.
• Include contingency clauses addressing potential duty changes after Jan. 19, 2029 or upon early termination of the Arrangement.

E. Compliance with related U.S. programs

• The Arrangement references MFN pricing models (e.g., GENEROUS, GLOBE, GUARD) and MFN/Tariff Agreements between UK companies and HHS/Commerce. While these are primarily domestic pricing mechanisms, importers should:
• Coordinate with legal and government affairs teams of UK suppliers to confirm that major UK pharmaceutical companies are entering and complying with the required MFN and Tariff Agreements, as non‑compliance could theoretically affect the no‑tariff commitment.
• Monitor HHS, CMS, and Commerce communications for any indication that the conditions for the no‑tariff commitments are not being met.

F. Recordkeeping and audit readiness

• Maintain documentation supporting:
• UK origin of imported pharmaceuticals and medical technologies.
• Correct HTS classification and absence of Section 232/301 Chapter 99 codes for covered UK-origin products during the relevant periods.
• Any CBP rulings or guidance relied upon.
• Prepare to respond to CBP inquiries or audits regarding:
• Origin determinations for UK‑sourced pharma/medtech.
• Justification for not applying Section 232/301 Chapter 99 provisions.

6. References and source documents

Primary Arrangement text:

• “Arrangement Between the Government of the United States of America and the Government of the United Kingdom of Great Britain and Northern Ireland on Pharmaceutical Pricing”
• PDF: https://ustr.gov/sites/default/files/files/Press/Releases/2026/U.S.-UK%20Pharma%20Pricing%20Arrangement%20-%204.2.2026.pdf

Related USTR press release:

• “Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing” (USTR press release page where the PDF is linked).

Operational follow‑up

• Importers and brokers should also monitor:
• Federal Register notices from USTR and Commerce regarding any Section 232 or 301 actions on pharmaceuticals, pharmaceutical ingredients, or medical technologies.
• CBP Cargo Systems Messaging Service (CSMS) for any implementation guidance on treatment of UK-origin pharmaceuticals and medical technologies under Section 232/301.

Summary of key compliance takeaway

• For UK-origin pharmaceuticals (including ingredients) and medical technologies, no additional Section 232/301 tariffs should apply during the specified periods (Dec. 1, 2025 or Jan. 1, 2026 through Jan. 19, 2029), assuming the Arrangement remains in force and conditions are met. Compliance teams must ensure correct origin determination, avoid unnecessary Chapter 99 declarations, and closely monitor for any policy changes, extensions, or termination notices that could alter this duty treatment.